PhRMA

article thumbnail

Three things to know from the latest Patient Experience Survey

PhRMA

Most insured Americans believe insurance should provide affordable access to health care (93%), but only a third (34%) say it does, according to the fourth installment of the Patient Experience Survey (PES). The survey — based on interviews with 5,000 Americans — explores this disconnect, detailing the challenges insured Americans face affording care and how practices by health insurers and middlemen put patient lifelines to access at risk.

Insurance 133
article thumbnail

Key considerations as Congress works towards PAHPA reauthorization

PhRMA

This week, PhRMA submitted comments to the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP) regarding the Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization draft. In our comments, we expressed our strong opposition to policy proposals that would inhibit the biopharmaceutical industry partnering with the government to address pressing public health needs.

233
233
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New studies add to body of evidence questioning 340B efficacy

PhRMA

Recent studies add to the growing body of evidence questioning the value of the current 340B program and whether it’s benefiting patients as Congress intended.

200
200
article thumbnail

Between hope and despair: Improving cancer outcomes

PhRMA

I can still see everything in the hospital room in my mind’s eye, the night — 13 days before Christmas — a neurologist delivered the news to my mother and me that she had non-Hodgkin’s lymphoma, an aggressive tumor lodged in her brain. It threw our little family into a panic and into a search for the best treatment available in the subsequent 8 months before her death.

Hospitals 184
article thumbnail

New report shows high-impact R&D happens after cancer medicines are first approved

PhRMA

A new report showcasing nine critical oncology treatments, highlights the vital role of post-approval research and development (R&D) in advancing cancer treatment options and delivering unprecedented progress in the fight against cancer over the past 10 years.

279
279
article thumbnail

A conversation with Dr. Mike Ybarra on the current state of COVID-19

PhRMA

On May 11th of this year, the COVID-19 national public health emergency (PHE) officially ended, marking an incredible milestone in the fight against COVID-19. While the end of the PHE signals a new chapter in the fight against COVID-19, the biopharmaceutical industry’s work continues to ensure our health care system is well-prepared for any curve balls this virus might throw as well as staying ahead of the next pandemic.

Vaccines 225
article thumbnail

More than 60 researchers ask Congress to support innovation

PhRMA

Earlier this month, 62 researchers from our member companies came to Washington, DC to meet with congressional offices during our annual fly-in event. This year included a record-breaking number of meetings — 145 over the course of the day.

250
250